Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15169160 | 0.98 | CYP1A2 (0.75) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL324058 | 0.98 | CYP1A2 (0.75) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL324283 | 0.87 | CYP1A2 (0.71) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL324385 | 0.87 | ALDH1A1 (0.72) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL323993 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL323661 | 0.85 | ALDH1A1 (1.00) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL324362 | 0.83 | ALDH1A1 (1.00) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL10237980 | 0.83 | ALDH1A1 (0.66) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL324331 | 0.83 | ALDH1A1 (0.66) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL10238861 | 0.81 | ALDH1A1 (0.60) | CYP1A2CYP2C19ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | claimed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | claimed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | claimed |
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | claimed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | claimed |
| EP-2590953-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2013-05-15 | — | — | EP | claimed |
| WO-2012004604-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2012-01-12 | — | — | WO | claimed |
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| EP-2590953-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004604-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | CYP1A2 654/4885CYP2C19 1661/4885ALDH1A1 2584/4885 |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | CYP1A2 654/4885CYP2C19 1661/4885ALDH1A1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.